Early, aggressive treatment of brain lesions caused by multiple sclerosis could help ward off faster decline in patients, a ...

A short course of Mavenclad can provide long-term reductions in disease activity and disability progression in highly active ...

Pathways to Cures Roadmap was created by a number of MS representatives and was endorsed by more than 30 organizations.

Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

The study, which utilised data from the French MS Registry, Italian MS Register, and the global MSBase Registry, analysed the outcomes of 282 patients with paediatric-onset MS.

Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.

Patients receiving chemotherapy in Lincolnshire can now have additional treatment to help reduce their hair loss. Many cancer ...

It's time to break down these barriers and ensure everyone with #MS gets the care they deserve. ’ Therapeutic inertia refers to the delay or avoidance of initiating or intensifying treatment for ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that could impact long-term health outcomes for women of ...

This roundup covers various health news highlights including the mpox outbreak in Africa and vaccine distribution issues, the ...

The seven-year MS-STAT study, which involved almost 1,000 patients over 31 sites across the UK, concluded that simvastatin is ...